Aptis PRUJ Prosthesis for the Treatment of Patients With Proximal Radial Ulna Joint Disorders.

March 21, 2023 updated by: Aptis Medical

A Prospective, Multi-Center, Single-Arm Clinical Trial of the Safety and Effectiveness of the Aptis PRUJ Prosthesis for the Treatment of Patients With Proximal Radial Ulna Joint Disorders.

A Prospective, Multi-Center, Single-Arm Clinical Trial of the safety and effectiveness of the Aptis PRUJ prosthesis for the treatment of patients with proximal radial ulna joint disorders

Study Overview

Detailed Description

This is a prospective, multi-center, single-arm clinical trial of the safety and effectiveness of the Aptis PRUJ prosthesis for the treatment of patients with proximal radial ulna joint disorders. A total of 84 patients will be enrolled in this trial with 9 centers participating in the US. The total study duration will be approximately 36 months, with an enrollment period of 12 months, followed by a 24 month follow-up period. Annual visits will continue until the last patient reaches the 2-year post-operative time point.

Study Type

Interventional

Enrollment (Anticipated)

84

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • In order to be eligible to participate in this study, subjects must meet all of the following criteria:

    1. Patient is skeletally mature and under 85 years of age.
    2. Patient has a painful, unstable radial head due to degeneration or post-traumatic disabilities presenting pain, crepitation, and decreased motion at the radiohumeral and/or proximal radioulnar joint and is otherwise
    3. Patients willing and able to understand and sign the informed consent. In the opinion of the Investigator, the patient has the understanding and willingness to comply with all study requirements including the post-operative rehabilitation and follow-up visits per protocol.

Exclusion Criteria:

  • 1. Inadequate bone stock or soft tissue coverage 2. Patients with severe humeral/ulnar arthritis, defined as:

    1. Pain at terminal flexion/extension
    2. Pain throughout ROM with loss of motion in terminal flexion and/or extension 3. Patients with an allergy to the implant materials 4. Active systemic infection or infection at the site of surgery 5. Physical interference with or by other prostheses during implantation or use 6. Have a Body Mass Index (BMI) greater than 35 kg/m2 7. Have any mental or psychological disorder that would impair the ability to complete the study questionnaires 8. Have significant comorbidities or conditions associated with high-risk for surgical or anesthetic survival (e.g., renal failure, peripheral vascular disease, unstable cardiac disease, poorly controlled diabetes, immunosuppression, etc.) 9. Have any medical condition or other circumstances that might interfere with the ability to return for follow-up visits in the judgment of the Investigator, including any systemic illness, neuromuscular, neurosensory, or musculoskeletal deficiency that would render the subject unable to perform appropriate post-operative rehabilitation 10. Have any condition which, in the judgment of the Investigator, would preclude adequate evaluation of the device's safety and performance 11. Skin, bone, circulatory and/or neurological deficiency at or affecting the implantation site 12. Prisoners 13. Patients on chronic corticosteroid or non-steroidal anti-inflammatory therapy 14. Women who are pregnant or breast-feeding or are planning to become pregnant during the study.

      15. Patients with a documented history of uncontrolled diabetes. 16. Patients with known allergies against anesthesia. 17. Patients with a history of or current drug and/or alcohol abuse 18. Patients unlikely to cooperate or are legally incompetent. 19. Patients with legal involvement, including an active claim for workman's compensation, or any other issue that would hinder completion of the two-year follow period.

      20. Patients who are participating or have participated in any other study involving an investigational drug or device within the past 3 months.

      Intra-operative Exclusion Criteria

      Subjects who meet any of the following intra-operative screening criteria will be excluded from participation in this study:

      • A proximal radio ulnar joint that cannot be reduced intraoperatively
      • Inadequate bone quality that would allow for implant placement
      • Not enough radius bone proximally for device implantation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Aptis PRUJ Prothesis
Investigational Aptis PRUJ Prothesis treatment
A prosthetic implant for replacement of the proximal radial ulna joint.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sucess
Time Frame: 24 months

A non-inferiority composite primary endpoint for effectiveness and safety, where a subject is considered a success if they meet the following criteria:

  • Mayo Elbow Performance Score, where success is defined as Good or Excellent at 24 months; and
  • Absence of radiographic evidence of periprosthetic osteolysis (radiolucent line >2mm around entire radial stem and ulnar screws), and no screw breakage at 24 months; and
  • Absence of device-related serious adverse events including any revisions and removals through 24 months
24 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effectiveness
Time Frame: 6 weeks, 3 months, 6 months, 12 months, 24 months

The following secondary endpoints will evaluate the effectiveness of the investigational device:

  • Pre- vs. Post-operative function assessed via Mayo Elbow Performance Score
  • Mayo Subscores

    • Pain
    • Range of motion
    • Instability
    • Function
6 weeks, 3 months, 6 months, 12 months, 24 months
Effectiveness
Time Frame: 6 weeks, 3 months, 6 months, 12 months, 24 months
Changes in overall health at all follow-up time points assessed via SF-36
6 weeks, 3 months, 6 months, 12 months, 24 months
Effectiveness
Time Frame: 6 weeks, 3 months, 6 months, 12 months, 24 months
Change in disability index assessed at all follow-up time points via DASH
6 weeks, 3 months, 6 months, 12 months, 24 months
Radiographic
Time Frame: 6 weeks, 3 months, 6 months, 12 months, 24 months
Radiolucencies around radial stem and ulnar screws
6 weeks, 3 months, 6 months, 12 months, 24 months
Radiographic
Time Frame: 6 weeks, 3 months, 6 months, 12 months, 24 months
Subsidence of radial component
6 weeks, 3 months, 6 months, 12 months, 24 months
Radiographic
Time Frame: 6 weeks, 3 months, 6 months, 12 months, 24 months
Screw breakage
6 weeks, 3 months, 6 months, 12 months, 24 months
Radiographic
Time Frame: 6 weeks, 3 months, 6 months, 12 months, 24 months
Ulnar variance
6 weeks, 3 months, 6 months, 12 months, 24 months
Health Economic
Time Frame: 6 weeks, 3 months, 6 months, 12 months, 24 months
Use of other concomitant medications
6 weeks, 3 months, 6 months, 12 months, 24 months
Health Economic
Time Frame: 6 weeks, 3 months, 6 months, 12 months, 24 months
Post-operative recovery time (return to daily activities/work)
6 weeks, 3 months, 6 months, 12 months, 24 months
Health Economic
Time Frame: 6 weeks, 3 months, 6 months, 12 months, 24 months
Post-operative rehabilitation details
6 weeks, 3 months, 6 months, 12 months, 24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Study Chair: John Scheker, Aptis Medical

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

June 1, 2023

Primary Completion (Anticipated)

November 1, 2025

Study Completion (Anticipated)

November 1, 2026

Study Registration Dates

First Submitted

March 10, 2023

First Submitted That Met QC Criteria

March 21, 2023

First Posted (Actual)

April 4, 2023

Study Record Updates

Last Update Posted (Actual)

April 4, 2023

Last Update Submitted That Met QC Criteria

March 21, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • AP-PRO-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Arthritis

Clinical Trials on Aptis PRUJ Prosthesis

3
Subscribe